Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected Antiretroviral Treatment Experienced Children and Adolescents

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00766597
First received: October 3, 2008
Last updated: September 3, 2014
Last verified: September 2014

October 3, 2008
September 3, 2014
August 2009
August 2010   (final data collection date for primary outcome measure)
  • Evaluation of suspected adverse drug reaction leading to treatment termination [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]
  • Adverse events of Grade 3 or higher severity [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]
  • Failure to meet PK targets [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00766597 on ClinicalTrials.gov Archive Site
  • Virologic failure as defined in protocol [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • Changes in co-receptor tropism [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • Primary response variables, including pharmacokinetic parameters [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • Secondary response variables, including CD4 counts and percent, polymerase genome and envelope sequence, and plasma HIV RNA PCR [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected Antiretroviral Treatment Experienced Children and Adolescents
Phase I/II Open-Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Vicriviroc (SCH-417690) a Novel CCR5 Antagonist in Combination Regimens in HIV-Infected Antiretroviral Therapy Experienced Children and Adolescents

Complications with current HIV antiretroviral therapy have left many children and adolescents with limited therapeutic options due to drug resistance. The purpose of this study is to test the effectiveness and safety of Vivriviroc (VCV), an HIV entry inhibitor and CCR5 co-receptor antagonist.

Highly active antiretroviral therapy (HAART)that includes a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI) has become the standard treatment of HIV-infected adults and children. When effective, HAART decreases the viral population, increases the body's immune responses, and leads to decreased disease progression and increased survival. However, several factors including poor adherence, drug toxicities, and drug resistance complicate HIV management and allow for children and adolescents to develop resistance to multiple drug classes, leaving them with very limited therapeutic options. Fortunately, drugs with new mechanisms of action, such as HIV entry inhibitors, demonstrate activity even in people with resistance to the currently available reverse transcriptase and protease inhibitors.

The purpose of this study is to test the effectiveness and safety of Vivriviroc (VCV), an HIV entry inhibitor. Vivriviroc targets the CCR5 chemokine receptor, which HIV uses to bind and enter CD4+ cells.

This study is a two-stage, age-stratified, non-comparative study to explore the safety, tolerability, pharmacokinetic profile and antiviral activity of the investigational CCR5 inhibitor vicriviroc in HIV-infected treatment experienced children and adolescents.

In Step I participants will be screened for the co-receptor CCR5 to assess whether they can enter Step II. Only participants with CCR5-tropic virus are eligible for Step II. Those participants who continue to Step II will be assigned to one of four age-stratifies cohorts which will receive varying forms, either liquid or tablet, of vicriviroc:

Cohort I: 12 years to less than 19 years of age, to receive tablet formulation of VCV

Cohort II: 6 years to less than 12 years of age, to receive tablet formulation of VCV

Cohort III: 6 years to less than 12 years of age, to receive liquid formulation of VCV

Cohort IV: 2 years to less than 6 years of age, to receive liquid formulation of VCV

Dose strengths of 20 mg and 30 mg will be used, or in liquid formulation at a concentration of 1mg/mL.

Step II is composed of Stage I and Stage II. Stage I is a dose ranging study designed to explore how the body responds to different doses of vicriviroc, including safety factors associated with dosage. After optimal dosage information and safety measures have been assessed for the different cohorts in Stage I, Stage II will open. Stage II will evaluate the long term safety, tolerability and effectiveness of vicriviroc.

The study, including Steps I and II will last for approximately 48 weeks. Follow-up for all subjects exposed to vicriviroc will last for 5 years after initial exposure. Visits will be every 3 months for subjects on study provided vicriviroc and every 6 months for subjects who discontinue vicriviroc.

Interventional
Phase 1
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
HIV Infections
Drug: Vicriviroc
Administered orally in either tablet or liquid form at a dosage of approximately 0.8/mg/kg every 24 hours, with a ritonavir boosted protease inhibitor containing background regimen
Experimental: A
Participants with CCR5-tropic virus
Intervention: Drug: Vicriviroc

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
9
August 2010
August 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Confirmed HIV infection
  • Treatment experienced subjects: Children or adolescents on an unchanged therapeutic regimen for at least 12 weeks and experiencing virologic failure OR participants on no treatment for 4 weeks or more but with history of virologic failure on a prior therapeutic regimen.
  • Likely to have virus that is sensitive to at least one ritonavir boosted protease inhibitor
  • HIV viral load greater than or equal to 1,000 copies/ml within 90 days prior to Step I entry
  • Able to swallow study medication, in tablets or liquid form specific to age-assigned cohort
  • Parent, legal guardian or participant able and willing to provide signed informed consent and to have the participant followed at the clinic site
  • Willing to use effective methods of contraception

Inclusion Criteria for Step II (In addition to the inclusion criteria for Step I):

  • Participant's plasma HIV tested at Step I must be R5 tropic
  • Genotypic sensitivity enabling the participant to take optimized background therapy (OBT) consisting of at least a ritonavir-based protease inhibitor. More information on this criterion can be found in the study protocol.

Exclusion Criteria:

  • Presence of any currently active AIDS defining illness or history of malignancy
  • History of a seizure disorder that requires current anti-seizure medication for control or at risk for seizures. Those with a history of febrile seizures alone are not excluded.
  • Certain abnormal laboratory values. More information on this criterion can be found in the protocol.
  • Any vaccinations 14 days prior to Step I, or scheduled to occur within 14 days prior to entry into Step II, and the week 24 and 48 visits in Step II
  • Allergy or sensitivity to study drug or its ingredients
  • Taking any Step II disallowed medications (see protocol) and unable or unwilling to discontinue them at least one week prior to entering Step II
  • Use of NNRTIs other than etravirine 21 days prior to Step II entry
  • Pregnancy or breastfeeding. Infants who are receiving breastmilk are allowed to enroll.

Exclusion Criteria for Step II

  • All exclusion criteria for Step I
  • Participants harboring dual or mixed tropic virus (R5/X4) or X4 virus or non phenotypable virus
  • Current or anticipated use of any disallowed medications
  • Use of efavirenz, nevirapine, and delavirdine for 21 days prior to Step II entry
  • Pregnant within 3 days of Step II entry
Both
2 Years to 18 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Puerto Rico
 
NCT00766597
P1071, 10634, IMPAACT P1071
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Study Chair: Rolando M Viani, M.D., M.T.P. University of California
Study Chair: Stephen A Spector, M.D. University of California, San Diego
National Institute of Allergy and Infectious Diseases (NIAID)
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP